Gathering the record
Relay is organizing the evidence and source boundaries.
Adamantane-derived small molecule
An experimental small molecule discussed for fatigue, stimulation, and anxiety. It is not a peptide.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Regional human trials examined asthenic symptoms; robust modern evidence for performance enhancement in healthy users is not established.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Modern controlled safety characterization is limited; stimulant-like, sleep, cardiovascular, neuropsychiatric, and misuse questions remain incompletely defined.
Controlled human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryNot FDA-approved; historically used or registered in limited jurisdictions and prohibited in sport by WADA. Clinical effectiveness, dose-response, misuse potential, cardiovascular and neuropsychiatric safety, and reproducibility outside older regional research.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
A Russian multicenter report analyzed 728 patients with asthenic symptoms and psychoautonomic syndrome.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| 28 days | 50–100 mg total daily dose | Daily |
This report lacked a placebo control. Its symptom changes do not establish a general performance-enhancement regimen, long-term safety, or benefit in healthy users.
Ladasten · multicenter asthenic-disorders report Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.The studied product was oral. This is not an intranasal concentration or a reconstitution instruction.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A regional randomized, blinded study compared Ladasten with placebo in patients with neurasthenia over a 28-day treatment period.
Population: Patients with neurasthenia
Design: Randomized blinded placebo-controlled clinical study
Mechanisms
Regional clinical studies examined asthenic symptoms, while animal studies describe neurologic and behavioral effects. These records do not establish broad performance benefits in healthy users.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Research reference
A reference for the studies, populations, and routes behind this profile.
Limited older human psychopharmacology and regional clinical literature; modern independent outcome evidence is sparse.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Clinical effectiveness, dose-response, misuse potential, cardiovascular and neuropsychiatric safety, and reproducibility outside older regional research.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Accessible methods are limited, and modern independent replication is sparse. It cannot establish durable benefit, misuse risk, cardiovascular safety, psychiatric safety, or effects across current products. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized blinded placebo-controlled clinical study
Patients with neurasthenia
The regional trial reported improvement in asthenic symptoms compared with placebo.
Study administration: Not stated in the current record.
Limitations: Limited accessible methods and modern independent replication constrain generalization to healthy users.
Animal neurologic and behavioral study
Rats
Endpoints were not fully described in the current record.
The study described dose- and sex-dependent neurologic and behavioral changes in rats.
Study administration: Not stated in the current record.
Limitations: Animal neurochemistry does not establish human therapeutic outcomes.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 19491814
PMID 11109517